abstract |
The present invention relates to the application of double-helical oligonucleotides (siRNA) interfering with the mRNA of gene involved in carcinogenesis, particularly the Wntl, Wnt2 or Her3 gene. Such oligonucleotides may be modified chemically, used in conjunction with viral and non-viral vectors such as lipid complexes. Such oligonucleotides exhibit unusual antiproliferative properties against tumour cells and may be used in anti-tumour treatment. |